Adar1 Capital Management, Llc Acquires 187,704 Shares of Tenax Therapeutics (NASDAQ:TENX) Stock

Posted by Geri Gentry on Sep 4th, 2026

Tenax Therapeutics, Inc. (NASDAQ:TENX – Get Free Report) major shareholder Adar1 Capital Management, Llc acquired 187,704 shares of the stock in a transaction on Wednesday, September 2nd. The shares were bought at an average price of $1.80 per share, with a total value of $337,867.20. Following the purchase, the insider directly owned 5,624,151 shares of the company’s stock, valued at $10,123,471.80. The trade was a 3.45% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Large shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Adar1 Capital Management, Llc also recently made the following trade(s):

On Tuesday, September 1st, Adar1 Capital Management, Llc bought 179,058 shares of Tenax Therapeutics stock. The stock was bought at an average cost of $1.80 per share, for a total transaction of $322,304.40.
On Monday, August 31st, Adar1 Capital Management, Llc purchased 403,571 shares of Tenax Therapeutics stock. The shares were bought at an average price of $1.79 per share, with a total value of $722,392.09.
On Monday, August 24th, Adar1 Capital Management, Llc purchased 107,374 shares of Tenax Therapeutics stock. The stock was bought at an average cost of $1.75 per share, with a total value of $187,904.50.
On Friday, August 21st, Adar1 Capital Management, Llc acquired 716,369 shares of Tenax Therapeutics stock. The shares were purchased at an average cost of $1.77 per share, for a total transaction of $1,267,973.13.
On Thursday, August 20th, Adar1 Capital Management, Llc acquired 202,124 shares of Tenax Therapeutics stock. The shares were purchased at an average cost of $1.78 per share, for a total transaction of $359,780.72.

Tenax Therapeutics Stock Performance

NASDAQ:TENX opened at $1.78 on Friday. The firm has a market cap of $66.61 million, a P/E ratio of -1.20 and a beta of 0.83. Tenax Therapeutics, Inc. has a fifty-two week low of $1.31 and a fifty-two week high of $19.40. The firm has a 50-day simple moving average of $10.09 and a two-hundred day simple moving average of $11.91.

Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last issued its earnings results on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.03. On average, equities research analysts predict that Tenax Therapeutics, Inc. will post -1.41 EPS for the current year.

Hedge Funds Weigh In On Tenax Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in TENX. Janus Henderson Group PLC grew its position in Tenax Therapeutics by 989.3% during the first quarter. Janus Henderson Group PLC now owns 1,815,474 shares of the specialty pharmaceutical company’s stock valued at $29,066,000 after buying an additional 1,648,808 shares during the period. Perceptive Advisors LLC raised its position in Tenax Therapeutics by 229.7% in the first quarter. Perceptive Advisors LLC now owns 1,447,782 shares of the specialty pharmaceutical company’s stock worth $23,150,000 after acquiring an additional 1,008,640 shares during the period. Braidwell LP purchased a new position in shares of Tenax Therapeutics during the 2nd quarter worth $8,503,000. Siren L.L.C. boosted its stake in shares of Tenax Therapeutics by 21.2% during the 4th quarter. Siren L.L.C. now owns 427,141 shares of the specialty pharmaceutical company’s stock worth $5,207,000 after acquiring an additional 74,700 shares during the last quarter. Finally, Bank of New York Mellon Corp purchased a new position in shares of Tenax Therapeutics during the 2nd quarter worth $4,733,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Wall Street Analyst Weigh In

TENX has been the subject of several research reports. Piper Sandler boosted their price objective on shares of Tenax Therapeutics from $20.00 to $50.00 and gave the company an “overweight” rating in a report on Friday, June 12th. Chardan Capital lowered shares of Tenax Therapeutics from a “buy” rating to a “neutral” rating and set a $5.00 target price for the company. in a research note on Tuesday, August 11th. William Blair cut Tenax Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, August 10th. Leerink Partners set a $4.00 price target on Tenax Therapeutics in a research note on Tuesday, August 11th. Finally, Weiss Ratings raised Tenax Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 28th. One equities research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $14.00.

Check Out Our Latest Stock Report on TENX

Tenax Therapeutics Company Profile

(Get Free Report)

Tenax Therapeutics, Inc is a clinical-stage specialty pharmaceutical company developing drug delivery technologies designed to improve pain management in acute care settings. The company’s proprietary platform leverages biodegradable polymer matrices to create sustained-release formulations of local anesthetics, aiming to extend the duration of pain relief while reducing reliance on opioid medications.

Tenax’s lead development programs focus on injectable formulations intended for infiltration and peripheral nerve block applications, with the goal of providing longer-lasting analgesia following surgical and procedural interventions.